SCHEMBL23623610

SCHEMBL23623610

Nc1cnc(N2CCN(CCC(F)(F)F)CC2)c(F)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.38
▸ SMN1; SMN2 Q16637 6/20 0.37
▸ ALDH1A1 P00352 5/20 0.37
▸ MAPT P10636 4/20 0.34
▸ MEN1 O00255 3/20 0.34
▸ KMT2A Q03164 3/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ LMNA P02545 2/20 0.34
▸ ADORA2A P29274 1/20 0.34
▸ TSHR P16473 2/20 0.33
▸ HTT P42858 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ NFKB1 P19838 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ THPO P40225 1/20 0.33
▸ MTOR P42345 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23622940 0.86 SCN10A (0.39) POLBSMN1; SMN2ALDH1A1MAPTMEN1
SCHEMBL23611965 0.85 POLB (0.50) POLBSMN1; SMN2ALDH1A1MAPTMEN1
SCHEMBL30411894 0.80 PIK3CA (0.45) SMN1; SMN2ALDH1A1MAPTMEN1KMT2A
SCHEMBL24215441 0.80 PIK3CA (0.45) SMN1; SMN2ALDH1A1MAPTMEN1KMT2A
SCHEMBL14070979 0.78 SMN1; SMN2 (0.50) SMN1; SMN2ALDH1A1MAPTKMT2ATSHR
SCHEMBL24215560 0.77 CASP1 (0.37) HTR1ADRD2DRD3
SCHEMBL19649847 0.76 ALDH1A1 (0.41) POLBSMN1; SMN2ALDH1A1MAPTMEN1
SCHEMBL29988378 0.75 GRIN2D (0.43) SMN1; SMN2MAPTLMNAHTR1ADRD2
SCHEMBL23612145 0.75 GRIN2D (0.43) SMN1; SMN2MAPTLMNAHTR1ADRD2
SCHEMBL29739691 0.75 ALDH1A1 (0.43) POLBALDH1A1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230127839-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-04-27 — — US disclosed
US-20230127839-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-04-27 — — US disclosed
WO-2021138434-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2021-07-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230127839-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 POLB 430/4885SMN1; SMN2 2298/4885ALDH1A1 4654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback